text: <unk>  is a direct thrombin inhibitor that is FDA approved for the prophylaxis of patients undergoing percutaneous transluminal coronary angioplasty (PTCA) and patients with unstable angina or risk of heparin induced thrombocytopenia (HIT) undergoing percutaneous coronary intervention (PCI)..   Common adverse reactions include bleeding, headache, thrombocytopenia and fever.
option_0: Bivalirudin
option_1: Hirudin
option_2: Desirudin
option_3: Lepirudin 
option_4: Otamixaban
option_5: Argatroban
option_6: Lusutrombopag
option_7: Avatrombopag